US20020045583A1 - Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use - Google Patents
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use Download PDFInfo
- Publication number
- US20020045583A1 US20020045583A1 US09/773,772 US77377201A US2002045583A1 US 20020045583 A1 US20020045583 A1 US 20020045583A1 US 77377201 A US77377201 A US 77377201A US 2002045583 A1 US2002045583 A1 US 2002045583A1
- Authority
- US
- United States
- Prior art keywords
- prophylaxis
- compound
- treatment
- formula
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*NC.CCCCC1(C)CS(=O)(=O)c2ccc(N(C)C)cc2C(c2ccccc2)C1C Chemical compound C*NC.CCCCC1(C)CS(=O)(=O)c2ccc(N(C)C)cc2C(c2ccccc2)C1C 0.000 description 7
- YDAHAPQQDMBSMN-VGEXLYPQSA-N C.C.CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1C.C[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound C.C.CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1C.C[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YDAHAPQQDMBSMN-VGEXLYPQSA-N 0.000 description 1
- URCPHNIZJDAPFW-GDJZANQRSA-N C.CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound C.CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO URCPHNIZJDAPFW-GDJZANQRSA-N 0.000 description 1
- ARTSRIGETCWHRR-RNAQZQGESA-N CC([C@@H]([C@H]([C@@H]([C@@H](CO)O)[O]#CO[C@H](CO)[C@H]([C@@H]([C@H](CNC)[O]#C)[O]=C)[O]#C)[O]=C)[O]#C)=O Chemical compound CC([C@@H]([C@H]([C@@H]([C@@H](CO)O)[O]#CO[C@H](CO)[C@H]([C@@H]([C@H](CNC)[O]#C)[O]=C)[O]#C)[O]=C)[O]#C)=O ARTSRIGETCWHRR-RNAQZQGESA-N 0.000 description 1
- TYCZMRMKDNHJCV-GBQAPAEPSA-N CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O Chemical compound CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O TYCZMRMKDNHJCV-GBQAPAEPSA-N 0.000 description 1
- GNXFQWIHNCDOGS-QSABCGTDSA-N CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O Chemical compound CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O GNXFQWIHNCDOGS-QSABCGTDSA-N 0.000 description 1
- HLHGTKNTWZZMJJ-WQCPRJNWSA-N CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O Chemical compound CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O HLHGTKNTWZZMJJ-WQCPRJNWSA-N 0.000 description 1
- DEPXBGYNFSVAEW-HFEMYQFPSA-N CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@H]1O.CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@@H]1O Chemical compound CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@H]1O.CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@@H]1O DEPXBGYNFSVAEW-HFEMYQFPSA-N 0.000 description 1
- BJJQYJQNYGGVNZ-DRNWNIILSA-N CCCC[C@@](CC)(CS(c(c([C@@H]1C(C)(C2)C=CC=C2N)c2)ccc2N(C)C)(=O)=O)[C@H]1O Chemical compound CCCC[C@@](CC)(CS(c(c([C@@H]1C(C)(C2)C=CC=C2N)c2)ccc2N(C)C)(=O)=O)[C@H]1O BJJQYJQNYGGVNZ-DRNWNIILSA-N 0.000 description 1
- GJGIOTYMECWWOR-UFZKGGJDSA-N CCCC[C@@](CC)(CS(c(c([C@@H]1c2cc(NC([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@H]1O Chemical compound CCCC[C@@](CC)(CS(c(c([C@@H]1c2cc(NC([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@H]1O GJGIOTYMECWWOR-UFZKGGJDSA-N 0.000 description 1
- YFRFCXOPGVANAD-OHAYKYCFSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCCCCCCCNC(=O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCCCCCCCNC(=O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCCCCCCCNC(=O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCCCCCCCNC(=O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O YFRFCXOPGVANAD-OHAYKYCFSA-N 0.000 description 1
- XYEBVKBXXLROGZ-MFIVJREJSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(N)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(N)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(N)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(N)=CC=C2)[C@H]1O XYEBVKBXXLROGZ-MFIVJREJSA-N 0.000 description 1
- VYOXMGINRRXZCX-YKZCKYLCSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCBr)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCBr)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCBr)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCBr)=CC=C2)[C@H]1O VYOXMGINRRXZCX-YKZCKYLCSA-N 0.000 description 1
- DOGLXFVGYUZLAZ-IRGYVCFJSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCN(C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)C(C)=O)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCN(C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)C(C)=O)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCN(C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)C(C)=O)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCN(C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)C(C)=O)=CC=C2)[C@H]1O DOGLXFVGYUZLAZ-IRGYVCFJSA-N 0.000 description 1
- OFVKCWIBZIAUQA-XQPDPMEVSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O OFVKCWIBZIAUQA-XQPDPMEVSA-N 0.000 description 1
- VMYUEMFRGCZACG-ZWGIHKPLSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@H]1O VMYUEMFRGCZACG-ZWGIHKPLSA-N 0.000 description 1
- RUPJIRPNNQJBAP-XJNMJILVSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O RUPJIRPNNQJBAP-XJNMJILVSA-N 0.000 description 1
- IDOQCEHMQXFIDY-JTNWAJJNSA-P CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCC[N+](CC)(CC)CC)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCC[N+](CC)(CC)CC)=CC=C2)[C@H]1O.O=C([O-])C(F)(F)F.O=C([O-])C(F)(F)F Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)CCCC[N+](CC)(CC)CC)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCC[N+](CC)(CC)CC)=CC=C2)[C@H]1O.O=C([O-])C(F)(F)F.O=C([O-])C(F)(F)F IDOQCEHMQXFIDY-JTNWAJJNSA-P 0.000 description 1
- PECSCRDTQUKKFG-MAWHRFDESA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O PECSCRDTQUKKFG-MAWHRFDESA-N 0.000 description 1
- QCGMXTLCAVBKJG-WZEOMWABSA-N CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@H]1O Chemical compound CCCC[C@@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O)=CC=C2)[C@H]1O QCGMXTLCAVBKJG-WZEOMWABSA-N 0.000 description 1
- KAOKHPGCPUOUPG-WXFUMESZSA-N CCCC[C@](CC)(CS(c(c([C@H]1c2cc(N)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O Chemical compound CCCC[C@](CC)(CS(c(c([C@H]1c2cc(N)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O KAOKHPGCPUOUPG-WXFUMESZSA-N 0.000 description 1
- GJGIOTYMECWWOR-BXLFYZMHSA-N CCCC[C@](CC)(CS(c(c([C@H]1c2cccc(NC([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)=O)c2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O Chemical compound CCCC[C@](CC)(CS(c(c([C@H]1c2cccc(NC([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)=O)c2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O GJGIOTYMECWWOR-BXLFYZMHSA-N 0.000 description 1
- SUEGRZBYDTZLIM-QTRQJRENSA-N CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(N)=CC=C2)[C@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac])=CC=C2)C1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.O=C(O)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac].O=[3H]#[3H]=[U] Chemical compound CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(N)=CC=C2)[C@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac])=CC=C2)C1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.O=C(O)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac].O=[3H]#[3H]=[U] SUEGRZBYDTZLIM-QTRQJRENSA-N 0.000 description 1
- FRUPUSVXHCJEOI-XBAMTZTFSA-N CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(N)=CC=C2)[C@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCCCCCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.NCCCCCCCCCCC(=O)O.O=C(Cl)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac].O=C(O)CCCCCCCCCCNC(=O)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac] Chemical compound CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(N)=CC=C2)[C@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCCCCCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.NCCCCCCCCCCC(=O)O.O=C(Cl)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac].O=C(O)CCCCCCCCCCNC(=O)C(O[Ac])C(O[Ac])C(O[Ac])C(CO[Ac])O[Ac] FRUPUSVXHCJEOI-XBAMTZTFSA-N 0.000 description 1
- BAICKDVLVASHPY-PMYOPHBMSA-N CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCBr)=CC=C2)[C@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCBr)=CC=C2)[C@H]1O.CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O.NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO BAICKDVLVASHPY-PMYOPHBMSA-N 0.000 description 1
- WOQRXFBBHJZKOC-RDVQCKJUSA-N CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O Chemical compound CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(N(C)C)C=C2)[C@@H](C2=CC(NC(=O)CCCCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C2)[C@H]1O WOQRXFBBHJZKOC-RDVQCKJUSA-N 0.000 description 1
- IWLDMVAFGNMHIU-VZFHVOOUSA-N C[C@@H](C[C@H]([C@@H]1[O]#C)O)O[C@@H]1C(O)=O Chemical compound C[C@@H](C[C@H]([C@@H]1[O]#C)O)O[C@@H]1C(O)=O IWLDMVAFGNMHIU-VZFHVOOUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to substituted benzothiepine 1,1-dioxide derivatives, their physiologically tolerable salts and physiologically functional derivatives.
- One object of the present invention is the improved availability of compounds which display a therapeutically utilizable hypolipidemia action.
- novel compounds satisfy this object when they bring about the same magnitude of fecal bile acid excretion at a significantly lower dosage than that required of currently-known compounds.
- a dose reduction of the ED 200 value by at least a factor of 5 compared with the compounds currently known is particularly desirable.
- the present invention unexepectedly satisfies this object.
- R 1 is methyl, ethyl, propyl, or butyl
- R 2 is H, OH, NH 2 , or NH-(C 1 -C 6 )-alkyl
- R 3 is a sugar radical, a disugar radical, a trisugar radical, or a tetrasugar radical, wherein said radicals are optionally mono- or polysubstituted by a sugar protective group;
- R 4 is methyl, ethyl, propyl, or butyl
- R 5 is methyl, ethyl, propyl, or butyl
- Z is —(C ⁇ O) n -(C 0 -C 16 )-alkyl-, —(C ⁇ O) n -(C 0 -C 16 )-alkyl-NH—, —(C ⁇ O) n -(C 0 -C 16 )-alkyl-O—, —(C ⁇ O) n -(C 1 -C 16 )-alkyl-(C ⁇ O) m , or a covalent bond;
- n is 0 or 1;
- m is 0 or 1;
- Preferred compounds of formula I are those in which one or more radicals have the following meaning:
- R 1 is ethyl, propyl, or butyl
- R 2 is H, OH, NH 2 , or NH-(C 1 -C 6 )-alkyl
- R 3 is a sugar radical, or disugar radical, wherein said radicals are optionally mono- or polysubstituted by a sugar protective group;
- R 4 is methyl, ethyl, propyl, or butyl
- R 5 is methyl, ethyl, propyl, or butyl
- Z is —(C ⁇ O) n -(C 0 -C 16 )-alkyl-, —(C ⁇ O) n—(C 0 -C 16 )-alkyl-NH—, —(C ⁇ O) n -(C 0 -C 16 )-alkyl-O—, —(C ⁇ O) n -(C 1 -C 16 )-alkyl-(C ⁇ O) m , or a covalent bond;
- n is 0 or 1;
- m is 0 or 1;
- R 1 is ethyl or butyl
- R 2 is OH
- R 3 is a sugar radical, wherein the sugar radical is optionally mono- or polysubstituted by a sugar protective group;
- R 4 is methyl
- R 5 is methyl
- Z is —(C ⁇ O)—(C O -C 4 )-alkyl, or a covalent bond
- Suitable pharmaceutically tolerable salts are particularly suitable for medicinal applications. These salts must have a pharmaceutically tolerable anion or cation.
- Suitable pharmaceutically tolerable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acid, and of organic acids, such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acid.
- the chlorine salt is particularly preferably used.
- Suitable pharmaceutically tolerable basic salts are ammonium salts
- Salts with an anion or cation which is not pharmaceutically tolerable are likewise included in the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically- tolerable salts and/or for use in nontherapeutic, for example in-vitro, applications.
- physiologically functional derivative indicates any physiologically tolerable derivative of a compound according to the invention, e.g. an ester which, on administration to a mammal, such as, for example, man, is able to form, directly or indirectly, such a compound or an active metabolite thereof.
- a further aspect of this invention are prodrugs of the compounds according to the invention.
- Such prodrugs can be metabolized in vivo to give a compound according to the invention.
- These prodrugs can themselves be active or inactive.
- the compounds according to the invention can also be present in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds according to the invention are included in the scope of the invention and are a further aspect of the invention.
- the compounds of formula I and their pharmaceutically tolerable salts and physiologically functional derivatives are ideal pharmaceuticals for the prophylaxis and treatment of lipid metabolism disorders, in particular of hyperlipidemia.
- the compounds of formula I are likewise suitable for influencing, in particular, lowering, the serum cholesterol level and for the prophylaxis and treatment of one or more arteriosclerotic symptoms.
- these compounds are used for prophylaxis, one skilled in the art has many means to determine or predict a patient's need for such prophylaxis. These methods are well-known in the art.
- the compounds can optionally also be administered in combination with statins, such as, for example, simvastatin, fluvastatin, pravastatin, cerivastatin, lovastatin or atorvastatin.
- statins such as, for example, simvastatin, fluvastatin, pravastatin, cerivastatin, lovastatin or atorvastatin.
- the compounds according to the invention are also suitable for the prophylaxis or treatment-of gallstones.
- the amount of a compound according to formula I which is necessary in order to achieve the desired biological effect is dependent on a number of factors, e.g. the specific compound selected, the intended use, in particular whether for prophylaxis or for treatment, the manner of administration and the clinical condition of the patient.
- the daily dose is in the range from 0.1 mg to 100 mg (typically from 0.1 mg to 50 mg) per day per kilogram of body weight, e.g. 0.1-10 mg/kg/day.
- Tablets or capsules can contain, for example, from 0.01 to 100 mg, typically from 0.02 to 50 mg.
- the abovementioned weight data relate to the weight of the benzothiepine ion derived from the salt.
- the compounds according to formula I can be used themselves as the compound, but preferably they are present in the form of a pharmaceutical composition with at least one pharmacologically tolerable excipient.
- the excipient must of course be tolerable in the sense that it is compatible with the other constituents of the composition and is not harmful to the health of the patient.
- the excipient can be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example as a tablet, which can contain from 0.05% to 95% by weight of the compound of formula I.
- Further pharmaceutically active substances can also be present, including further compounds according to formula I.
- compositions according to the invention can be prepared by one of the known pharmaceutical methods, which essentially consists in mixing the constituents with pharmacologically tolerable excipients and/or auxiliaries.
- Pharmaceutical compositions according to the invention are those which are suitable for oral and peroral (e.g. sublingual) administration, although the most suitable manner of administration is dependent in each individual case on the nature and severity of the condition to be treated and on the type of the compound according to formula (I) used in each case.
- Coated formulations and coated delayed-release formulations are also included in the scope of the invention.
- Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
- Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, lozenges or tablets, which in each case contain a specific amount of the compound according to formula (I); as a powder or granules; as a solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- these compositions can be prepared according to any suitable pharmaceutical method which includes a step in which the active compound and the excipient (which can consist of one or more additional constituents) are brought into contact.
- compositions are prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product, if necessary, is shaped.
- a tablet can thus be prepared by pressing or shaping a powder or granules of the compound, if appropriate with one or more additional constituents.
- Pressed tablets can be produced by tableting the compound in free-flowing form, such as, for example, a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or one or more surface-active agents and/or one or more dispersing agents in a suitable machine.
- Shaped tablets can be produced by shaping the compound in powder form moistened with an inert liquid diluent in a suitable machine.
- compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound according to formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
- the invention furthermore relates both to isomer mixtures of formula I, and the pure stereoisomers of formula I, as well as diastereomer mixtures of formula I and the pure diastereomers.
- Resolution of enantiomerically pure compounds is performed by methods well-known in the art. For example, a chiral acid or base can be added to a racemic or diastereomer mixture, and separation is then performed chromatographically. Another possible method uses a chirally selective chromatography column to resolve the mixture.
- Preferred-racemates and enantiomerically pure compounds of formula I are those having the following structure:
- Sugar radicals are understood as meaning compounds which are derived from aldoses and ketoses having 3 to 7 carbon atoms and which can belong to the D or L series; these also include amino sugar, sugar alcohols or sugar acids. Examples which may be mentioned are glucose, mannose, fructose, galactose, ribose, erythrose, glyceraldehyde, sedoheptulose, glucosamine, galactosamine, glucuronic acid, galacturonic acid, gluconic acid, galactonic acid, mannonic acid, glucamine, 3-amino-1,2-propanediol, glucaric acid and galactaric acid.
- Preferred sugar radicals are:
- sugar radicals are:
- Disugars mean saccharides which consist of two sugar units. Di-, tri- or tetrasaccharides are formed by acetal-like bonding of 2 or more sugars. The bonds can in this case occur in the ⁇ or ⁇ form. Examples which may be mentioned are lactose, maltose and cellobiose.
- the substitution preferably takes place with the hydrogen atom of an OH group of the sugar.
- Possible protective groups for the hydroxyl groups of the sugars are preferably the following: benzyl, acetyl, benzoyl, pivaloyl, trityl, tert-butyidimethylsilyl, benzylidene, cyclohexylidene or isopropylidene protective groups. These protective groups are referred to herein as “sugar protective groups.”
- the invention furthermore relates to a process for the preparation of benzothiepine 1,1dioxide derivatives of formula I:
- the biological testing of the compounds according to the invention was carried out by determination of the ED 200 excretion. This testing investigates the action of the compounds according to the invention on the bile acid transport in the ileum and the fecal excretion of bile acids in the rat after oral administration twice daily. The diastereomer mixtures of the compounds were tested.
- mice Male Wistar rats (Kastengrund, Hoechst AG, weight range 250-350 g) were kept in groups of 6 animals each and received a standard feed mixture (Altromin, Germany) from 10 days before the start of treatment (day 1) with a reversed day/night rhythm (4.00-16.00 dark, 16.00-4.00 light). Three days before the start of the experiment (day 0), the animals were divided into groups of 4 animals each. TABLE 1 Division of the animals into treatment groups: Number of the Animal No./ Test substance 1 group Analysis No.
- the excretion of 14 C taurocholic acid was expressed as a percentage proportion of the corresponding values of the control group (treated with vehicle).
- the ED 200 i.e.
- the dose which increases the fecal excretion of 14 C taurocholic acid to 200% of the control group is calculated from a sigmoid or linear dose-response curve by interpolation.
- the calculated ED 200 corresponds to a dose which doubles the fecal excretion of-bile acids.
- Table 2 shows measurements of the ED 200 excretion. TABLE 2 ED 200 excretion (mg/kg/d) p.o. Compounds from Example (diastereomer mixture) 1 0.009 2 0.008 3 0.04 5 0.03 6 0.04 7 0.04 8 0.007 9 0.007 10 0.04 3 (pure structure 11a) 0.008 Comparison Examples 1 0.8 2 1.0 3 0.9
Abstract
Description
- The invention relates to substituted benzothiepine 1,1-dioxide derivatives, their physiologically tolerable salts and physiologically functional derivatives.
- The present application is a continuation of PCT application PCT/EP99/03743, which designates the United States, and was filed May 29,1999. The present application and the PCT application claim priority to German patent No. 19825804.6, filed Jun. 10, 1998, and issued Apr. 16, 1999. Both prior applications are entirely incorporated by reference herein.
- Benzothiepine 1,1-dioxide derivatives and their use for the treatment of hyperlipidemia as well as arteriosclerosis and hypercholesterolemia have already been described. PCT Application No. PCT/US97104076, publication No. WO 97/33882. The disclosure of that publication is entirely incorporated by reference herein.
- One object of the present invention is the improved availability of compounds which display a therapeutically utilizable hypolipidemia action. In particular, novel compounds satisfy this object when they bring about the same magnitude of fecal bile acid excretion at a significantly lower dosage than that required of currently-known compounds. A dose reduction of the ED200 value by at least a factor of 5 compared with the compounds currently known is particularly desirable. The present invention unexepectedly satisfies this object.
-
- in which
- R1 is methyl, ethyl, propyl, or butyl;
- R2 is H, OH, NH2, or NH-(C1-C6)-alkyl;
- R3 is a sugar radical, a disugar radical, a trisugar radical, or a tetrasugar radical, wherein said radicals are optionally mono- or polysubstituted by a sugar protective group;
- R4 is methyl, ethyl, propyl, or butyl;
- R5 is methyl, ethyl, propyl, or butyl;
- Z is —(C═O)n-(C0-C16)-alkyl-, —(C═O)n-(C0-C16)-alkyl-NH—, —(C═O)n-(C0-C16)-alkyl-O—, —(C═O)n-(C1-C16)-alkyl-(C═O)m, or a covalent bond;
- n is 0 or 1;
- m is 0 or 1;
- and their pharmaceutically tolerable salts and physiologically functional derivatives.
- Preferred compounds of formula I are those in which one or more radicals have the following meaning:
- R1 is ethyl, propyl, or butyl;
- R2 is H, OH, NH2, or NH-(C1-C6)-alkyl;
- R3 is a sugar radical, or disugar radical, wherein said radicals are optionally mono- or polysubstituted by a sugar protective group;
- R4 is methyl, ethyl, propyl, or butyl;
- R5 is methyl, ethyl, propyl, or butyl;
- Z is —(C═O)n-(C0-C16)-alkyl-, —(C═O)n—(C 0-C16)-alkyl-NH—, —(C═O)n-(C0-C16)-alkyl-O—, —(C═O)n-(C1-C16)-alkyl-(C═O)m, or a covalent bond;
- n is 0 or 1;
- m is 0 or 1;
- and their pharmaceutically tolerable salts.
- Particularly preferred compounds of formula I are those in which one or more radicals have the following meaning:
- R1 is ethyl or butyl;
- R2 is OH;
- R3 is a sugar radical, wherein the sugar radical is optionally mono- or polysubstituted by a sugar protective group;
- R4 is methyl;
- R5 is methyl;
- Z is —(C═O)—(CO-C4)-alkyl, or a covalent bond;
- and their pharmaceutically tolerable salts.
- On account of their higher water solubility compared with the starting or base compounds, pharmaceutically tolerable salts are particularly suitable for medicinal applications. These salts must have a pharmaceutically tolerable anion or cation. Suitable pharmaceutically tolerable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acid, and of organic acids, such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acid. For medicinal purposes, the chlorine salt is particularly preferably used. Suitable pharmaceutically tolerable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).
- Salts with an anion or cation which is not pharmaceutically tolerable are likewise included in the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically- tolerable salts and/or for use in nontherapeutic, for example in-vitro, applications.
- The term “physiologically functional derivative” used here indicates any physiologically tolerable derivative of a compound according to the invention, e.g. an ester which, on administration to a mammal, such as, for example, man, is able to form, directly or indirectly, such a compound or an active metabolite thereof.
- A further aspect of this invention are prodrugs of the compounds according to the invention. Such prodrugs can be metabolized in vivo to give a compound according to the invention. These prodrugs can themselves be active or inactive.
- The compounds according to the invention can also be present in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds according to the invention are included in the scope of the invention and are a further aspect of the invention.
- Below, all references to “compound(s) according to formula I” refer to compound(s) of formula I as described above, and also their salts, solvates and physiologically functional derivatives as described herein.
- The compounds of formula I and their pharmaceutically tolerable salts and physiologically functional derivatives are ideal pharmaceuticals for the prophylaxis and treatment of lipid metabolism disorders, in particular of hyperlipidemia. The compounds of formula I are likewise suitable for influencing, in particular, lowering, the serum cholesterol level and for the prophylaxis and treatment of one or more arteriosclerotic symptoms. When these compounds are used for prophylaxis, one skilled in the art has many means to determine or predict a patient's need for such prophylaxis. These methods are well-known in the art.
- The compounds can optionally also be administered in combination with statins, such as, for example, simvastatin, fluvastatin, pravastatin, cerivastatin, lovastatin or atorvastatin.
- The compounds according to the invention are also suitable for the prophylaxis or treatment-of gallstones.
- The amount of a compound according to formula I which is necessary in order to achieve the desired biological effect is dependent on a number of factors, e.g. the specific compound selected, the intended use, in particular whether for prophylaxis or for treatment, the manner of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.1 mg to 100 mg (typically from 0.1 mg to 50 mg) per day per kilogram of body weight, e.g. 0.1-10 mg/kg/day. Tablets or capsules can contain, for example, from 0.01 to 100 mg, typically from 0.02 to 50 mg. In the case of pharmaceutically tolerable salts, the abovementioned weight data relate to the weight of the benzothiepine ion derived from the salt. For the prophylaxis or therapy of the abovementioned conditions, the compounds according to formula I can be used themselves as the compound, but preferably they are present in the form of a pharmaceutical composition with at least one pharmacologically tolerable excipient. The excipient must of course be tolerable in the sense that it is compatible with the other constituents of the composition and is not harmful to the health of the patient. The excipient can be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example as a tablet, which can contain from 0.05% to 95% by weight of the compound of formula I. Further pharmaceutically active substances can also be present, including further compounds according to formula I. The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which essentially consists in mixing the constituents with pharmacologically tolerable excipients and/or auxiliaries. Pharmaceutical compositions according to the invention are those which are suitable for oral and peroral (e.g. sublingual) administration, although the most suitable manner of administration is dependent in each individual case on the nature and severity of the condition to be treated and on the type of the compound according to formula (I) used in each case. Coated formulations and coated delayed-release formulations are also included in the scope of the invention. Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
- Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, lozenges or tablets, which in each case contain a specific amount of the compound according to formula (I); as a powder or granules; as a solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared according to any suitable pharmaceutical method which includes a step in which the active compound and the excipient (which can consist of one or more additional constituents) are brought into contact. In general, the compositions are prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product, if necessary, is shaped. For example, a tablet can thus be prepared by pressing or shaping a powder or granules of the compound, if appropriate with one or more additional constituents. Pressed tablets can be produced by tableting the compound in free-flowing form, such as, for example, a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or one or more surface-active agents and/or one or more dispersing agents in a suitable machine. Shaped tablets can be produced by shaping the compound in powder form moistened with an inert liquid diluent in a suitable machine.
- Pharmaceutical compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound according to formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
- The invention furthermore relates both to isomer mixtures of formula I, and the pure stereoisomers of formula I, as well as diastereomer mixtures of formula I and the pure diastereomers. Resolution of enantiomerically pure compounds is performed by methods well-known in the art. For example, a chiral acid or base can be added to a racemic or diastereomer mixture, and separation is then performed chromatographically. Another possible method uses a chirally selective chromatography column to resolve the mixture.
-
- Sugar radicals are understood as meaning compounds which are derived from aldoses and ketoses having 3 to 7 carbon atoms and which can belong to the D or L series; these also include amino sugar, sugar alcohols or sugar acids. Examples which may be mentioned are glucose, mannose, fructose, galactose, ribose, erythrose, glyceraldehyde, sedoheptulose, glucosamine, galactosamine, glucuronic acid, galacturonic acid, gluconic acid, galactonic acid, mannonic acid, glucamine, 3-amino-1,2-propanediol, glucaric acid and galactaric acid.
-
-
- Disugars mean saccharides which consist of two sugar units. Di-, tri- or tetrasaccharides are formed by acetal-like bonding of 2 or more sugars. The bonds can in this case occur in the α or β form. Examples which may be mentioned are lactose, maltose and cellobiose.
- If the sugar is substituted, the substitution preferably takes place with the hydrogen atom of an OH group of the sugar.
- Possible protective groups for the hydroxyl groups of the sugars are preferably the following: benzyl, acetyl, benzoyl, pivaloyl, trityl, tert-butyidimethylsilyl, benzylidene, cyclohexylidene or isopropylidene protective groups. These protective groups are referred to herein as “sugar protective groups.”
-
- which comprises reacting an amine of formula II or a salt thereof, in which R1, R2, R4 and R5 have the meanings indicated for formula I, with a compound of formula III or a salt thereof, in which R3 and Z have the meanings indicated for formula I, with elimination of water to give a compound of formula I and optionally converting the compound of formula I obtained into a physiologically tolerable salt or a physiologically functional derivative. If the radical R3 is a monosugar radical, this radical can optionally also still be lengthened stepwise so as to give the disugar radical, trisugar radical or tetrasugar radical after bonding to the amine of formula II.
- The following findings confirm the pharmacological efficacy of the compounds according to the invention.
- The biological testing of the compounds according to the invention was carried out by determination of the ED200 excretion. This testing investigates the action of the compounds according to the invention on the bile acid transport in the ileum and the fecal excretion of bile acids in the rat after oral administration twice daily. The diastereomer mixtures of the compounds were tested.
- The test was carried out as follows:
- 1) Preparation of the Test and Reference Substances
- The following recipe was used for the formulation of an aqueous solution: the substances were dissolved in adequate volumes of an aqueous solution comprising Solutol (=polyethylene glycol 600 hydroxystearate; BASF, Ludwigshafen, Germany; Batch No. 1763), so that a final concentration of 5% of Solutol is present in the aqueous solution. The solutions/suspensions were administered orally in a dose of 5 ml/kg.
- 2) Experimental Conditions
- Male Wistar rats (Kastengrund, Hoechst AG, weight range 250-350 g) were kept in groups of 6 animals each and received a standard feed mixture (Altromin, Lage, Germany) from 10 days before the start of treatment (day 1) with a reversed day/night rhythm (4.00-16.00 dark, 16.00-4.00 light). Three days before the start of the experiment (day 0), the animals were divided into groups of 4 animals each.
TABLE 1 Division of the animals into treatment groups: Number of the Animal No./ Test substance1 group Analysis No. (See Table 2) Dose (mg/kg/d) 1 1-4 negative control Vehicle 2 5-8 Test substance 2 × 0.008 Dose 1 3 9-12 Test substance 2 × 0.02 Dose 2 4 13-16 Test substance 2 × 0.1 Dose 3 5 17-20 Test substance 2 × 0.5 Dose 4 - 3. Experimental Course
- After intravenous or subcutaneous administration of 5 μCi of-C-taurocholate per rat (day 0), the vehicles or test substances were given at 7.00-8.00 and at 15.00-16.00 on the following day (day 1) (treatment for one day).
- Stool samples for the analysis of14C-taurocholate were taken every 24 hours directly after the administration of the morning dose. The feces were weighed, stored at −18° C. and later suspended in 100 ml of demineralized water and homogenized (Ultra Turrax, Janke & Kunkel, IKA-Werk). Aliquot parts (0.5 g) were weighed and combusted on combustion lids (Combusto Cones, Canberra Packard) in a combustion apparatus (Tri Carb® 307 combuster Canberra Packard GmbH, Frankfurt am Main, Germany). The resulting 14CO2 was absorbed with Carbo-Sorb® (Canberra Packard). The following C radioactivity measurements were determined after addition of the scintillator (Perma-Fluor complete scintillation cocktail No. 6013187, Packard) to the samples with the aid of liquid scintillation counting (LSC). The fecal excretion of 14C-taurocholic acid was calculated as a cumulative and/or percentage residual radioactivity (see below).
- 4) Observations and Measurements
- The fecal excretion of14C-TCA was determined in combusted aliquot parts of the stool samples taken at 24-hour intervals, calculated as the “cumulative percentage” of the administered activity and expressed as a % of the residual activity (=remaining activity, i.e. administered activity minus the already excreted activity). For the calculation of the dose-response curves, the excretion of 14C taurocholic acid was expressed as a percentage proportion of the corresponding values of the control group (treated with vehicle). The ED200, i.e. the dose which increases the fecal excretion of 14C taurocholic acid to 200% of the control group, is calculated from a sigmoid or linear dose-response curve by interpolation. The calculated ED200 corresponds to a dose which doubles the fecal excretion of-bile acids.
- 5) Results
- Table 2 shows measurements of the ED200 excretion.
TABLE 2 ED200 excretion (mg/kg/d) p.o. Compounds from Example (diastereomer mixture) 1 0.009 2 0.008 3 0.04 5 0.03 6 0.04 7 0.04 8 0.007 9 0.007 10 0.04 3 (pure structure 11a) 0.008 Comparison Examples 1 0.8 2 1.0 3 0.9 - 6) Discussion
- It can be inferred from the measured data that the compounds of formula I according to the invention are more active by a factor of 20 to 100 compared with the compounds previously known.
- The following Examples serve to illustrate the invention in greater detail without restricting the scope of the invention to products and embodiments described in the Examples.
-
- C30H44N2O9S (608.76). MS (M+H)+=609.3
-
- C40H54N2O14S (818.40). MS (M+H)+=819.3
-
- C35H55N3O9S (693.91). MS (M+H)+=694.4
-
- C37H59N3O9S (721.96). MS (M+H)+=722.3
-
- C41H65N3O10S (792.05). MS (M+H)+=792.5
-
- C42H58N2O14S (846.97). MS (M+H)+=847.4
-
- C32H48N2O9S (636.80). MS (M+H)+=637.4
-
- C45H63N3O15S (918.06). MS (M+H)+=918.6
-
- C35H53N3O10S (707.88). MS (M+H)−=708.4
-
- C47H67N3O15S (946.12). MS (M+H)+=946.5
-
-
-
-
- Synthesis of Compound 3 as a Diastereomer Mixture:
- 300 mg (0.69 mmol) of 1a/b (preparation analogous to PCT/US97/04076) and 700 mg (1.7 mmol) of penta-O-acetyl-D-gluconic acid (Charles E. Braun and Clinton D. Cook, 5 ORG. SYNTH. 887 (1973), the relevant disclosure of which is incorporated by reference herein) are dissolved in 10 ml of DMF (dimethylformamide). 700 mg (2.1 mmol) of TOTU (Fluka), 250 mg (1.7 mmol) of oxime (ethyl hydroxyiminocyanoacetate; Fluka) and 0.7 ml (5.5 mmol) of NEM (4-ethylmorpholine) are added successively. After one hour at room temperature, the mixture is diluted with 100 ml of ethyl acetate and washed three times with water. The organic phase is dried over MgSO4, filtered and concentrated. The residue is purified by means of flash chromatography (ethyl acetate/n-heptane 2:1) and 502 mg (88%) of 3a/b are obtained as an amorphous solid. TLC (ethyl acetate/n-heptane 2:1) Rf=0.3. The product 3a/b has the same retention as the starting material la/b, but stains differently with 2 M sulfuric acid.
- C40H54N2O14S (818.40). MS (M+H)+=819.3.
- Synthesis of Compound 4 as a Diastereomer Mixture:
- 455 mg (0.55 mmol) of 3a/b are dissolved in 20 ml of methanol. After addition of 0.3 ml of a methanolic 1 M sodium methoxide solution, the mixture is allowed to stand at room temperature for one hour. It is then neutralized with methanolic HCl solution and concentrated. The residue is purified using flash chromatography (methylene chloride/methanol/conc. ammonia 30/5/1) and 280 mg (83%) of 4a/b are obtained as an amorphous solid. TLC (methylene chloride/methanol/conc. ammonia 30/5/1). Rf=0.2.
- C30H44N2O9S (608.76). MS (M+H)+=609.3.
- Synthesis of Compound 11 as a Diastereomer Mixture:
- 77 mg (0.013 mmol) of 30a/b (preparation analogous to PCT/US97/04076) are dissolved in 4 ml of DMF. After addition of 150 mg (0.082 mmol) of 10 (glucamine, Fluka), the mixture is heated at 80° C. for two hours. It is then diluted with 50 ml of ethyl acetate and washed three times with water. The organic phase is dried over MgSO4, filtered and concentrated. The residue is purified by means of flash chromatography (methylene chloride/methanol/conc. ammonia 30/5/1) and 55 mg (61%) of 11a/b are obtained as an amorphous solid. TLC (methylene chloride/methanol/conc. ammonia 30/5/1). Rf=0.3.
- C35H55N3O9S (693.91). MS (M+H)+=694.4.
- Synthesis of Compound 14:
-
- C27H43NO13 (589.64). MS (M+H)+=590.4.
- Synthesis of Compound 15 as a Diastereomer Mixture:
- 200 mg (0.34 mmol) of 14, 78 mg (0.18 mmol) of 1a/b, 240 mg of TOTU, 80 mg of oxime and 0.3 ml of NEM are reacted in 4 ml of DMF analogously to the procedure for compound 4. After flash chromatography (methylene chloride/methanol/conc. ammonia 30/5/1), 47 mg (33%, over two steps) of 15a/b are obtained as an amorphous solid. TLC (methylene chloride/methanol/conc. ammonia 30/5/1). Rf=0.2.
- C41H65N3O10S (792.05). MS (M+H)+=792.5.
- The invention may be embodied in other specific forms and those skilled in the art will recognize that various changes and modifications can be made without departing from the spirit or essential characteristics thereof. The present embodiment is, therefore, considered in all respects as illustrative and not restrictive. Embodiments are measured by the scope of the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (30)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/773,772 US6441022B1 (en) | 1998-06-10 | 2001-02-02 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US10/201,050 US6642269B2 (en) | 1998-06-10 | 2002-07-24 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US10/606,771 US7019023B2 (en) | 1998-06-10 | 2003-06-27 | Benzothiepine 1, 1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19825804 | 1998-06-10 | ||
DE19825804A DE19825804C2 (en) | 1998-06-10 | 1998-06-10 | 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds |
DE19825804.6 | 1998-06-10 | ||
PCT/EP1999/003743 WO1999064409A2 (en) | 1998-06-10 | 1999-05-29 | Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use |
US09/398,315 US6221897B1 (en) | 1998-06-10 | 1999-09-20 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US09/773,772 US6441022B1 (en) | 1998-06-10 | 2001-02-02 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/398,315 Continuation US6221897B1 (en) | 1998-06-10 | 1999-09-20 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/201,050 Continuation US6642269B2 (en) | 1998-06-10 | 2002-07-24 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020045583A1 true US20020045583A1 (en) | 2002-04-18 |
US6441022B1 US6441022B1 (en) | 2002-08-27 |
Family
ID=26046712
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/398,315 Expired - Lifetime US6221897B1 (en) | 1998-06-10 | 1999-09-20 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US09/773,772 Expired - Lifetime US6441022B1 (en) | 1998-06-10 | 2001-02-02 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US10/201,050 Expired - Lifetime US6642269B2 (en) | 1998-06-10 | 2002-07-24 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US10/606,771 Expired - Lifetime US7019023B2 (en) | 1998-06-10 | 2003-06-27 | Benzothiepine 1, 1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/398,315 Expired - Lifetime US6221897B1 (en) | 1998-06-10 | 1999-09-20 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/201,050 Expired - Lifetime US6642269B2 (en) | 1998-06-10 | 2002-07-24 | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US10/606,771 Expired - Lifetime US7019023B2 (en) | 1998-06-10 | 2003-06-27 | Benzothiepine 1, 1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
Country Status (1)
Country | Link |
---|---|
US (4) | US6221897B1 (en) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642268B2 (en) * | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US6262277B1 (en) * | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19825804C2 (en) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds |
WO2000068203A1 (en) * | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
JP2005501861A (en) * | 2001-08-22 | 2005-01-20 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Combinations of 1,4-benzothiepine 1,1-dioxide derivatives with other active substances and their use |
CA2459017A1 (en) * | 2001-08-28 | 2003-03-13 | Sankyo Company, Limited | Medicinal compositions containing angiotensin ii receptor antagonist |
US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
US7399777B2 (en) * | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
AU2002333456B2 (en) | 2001-08-31 | 2008-07-17 | Sanofi-Aventis Deutschland Gmbh | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators |
GB0121622D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
US7200144B2 (en) * | 2001-10-18 | 2007-04-03 | Qlogic, Corp. | Router and methods using network addresses for virtualization |
MXPA04003524A (en) * | 2001-11-02 | 2004-07-23 | Searle Llc | Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake. |
JP2003187146A (en) * | 2001-12-17 | 2003-07-04 | Matsushita Electric Ind Co Ltd | Data providing service system |
US7223796B2 (en) * | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
US7078404B2 (en) * | 2002-04-11 | 2006-07-18 | Sanofi-Aventis Deutschland Gmbh | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use |
US7049341B2 (en) * | 2002-06-07 | 2006-05-23 | Aventis Pharma Deutschland Gmbh | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use |
US7262220B2 (en) * | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
MXPA05000053A (en) * | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments. |
US20060062862A1 (en) * | 2002-07-23 | 2006-03-23 | Bernd Haber | Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances |
US20040157922A1 (en) * | 2002-10-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments |
US7208504B2 (en) * | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
DE10258007B4 (en) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments |
US20040138145A1 (en) * | 2002-12-12 | 2004-07-15 | Aventis Pharma S.A. | Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease |
DE10258008B4 (en) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclic fluoroglycoside derivatives, medicaments containing these compounds and methods of making these medicaments |
FR2848452B1 (en) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | APPLICATION OF INTESTINAL BILIARY ACID RECAPTURE INHIBITORS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE |
DE10261067A1 (en) * | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterol-lowering agent containing an n-3 fatty acid |
DE10261061A1 (en) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Dietary food to positively influence cardiovascular health |
US20040242583A1 (en) * | 2003-01-20 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use |
US7179941B2 (en) * | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10306250A1 (en) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
US7196114B2 (en) * | 2003-02-17 | 2007-03-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use |
GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
DE10308355A1 (en) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments |
US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
US7173151B2 (en) * | 2003-02-27 | 2007-02-06 | Sanofi-Aventisdeutschand Gmbh | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
DE10308353A1 (en) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as medicines |
DE10308351A1 (en) * | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments |
DE10308352A1 (en) * | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments |
US7501440B2 (en) * | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
DE10314610A1 (en) * | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use |
US7094800B2 (en) * | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) * | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) * | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (en) * | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituted benzoylureido-o-benzoylamides, process for their preparation and their use |
AU2004293013B2 (en) | 2003-11-19 | 2011-04-28 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
US7470706B2 (en) * | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7498341B2 (en) * | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7402674B2 (en) * | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
DE102004005172A1 (en) * | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazole derivatives as inhibitors of the hormone sensitive lipase |
EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
DE102005026762A1 (en) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases |
DE102005033100B3 (en) * | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation |
DE102005033099A1 (en) * | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicines containing it and its use |
BRPI0617207A2 (en) | 2005-09-29 | 2011-07-19 | Sanofi Aventis | phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and use as pharmaceuticals |
EP2383271B1 (en) | 2006-03-13 | 2013-07-10 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolones as GSK-3 Inhibitors |
US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
DE102006028862A1 (en) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-amino-imidazo [1,2-a] pyridine |
EP2061767B1 (en) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
EP2083832B1 (en) * | 2006-11-14 | 2011-01-05 | Sanofi-Aventis Deutschland GmbH | Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof |
DE102006053636B4 (en) * | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | New cyclohexyl substituted 1,4-benzothiepine 1,1-dioxide derivatives and their use |
DE102006053635B4 (en) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Novel benzyl-substituted 1,4-benzothiepine-1,1-dioxide derivatives, drugs containing these compounds and their use |
DE102006053637B4 (en) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Novel fluorine-substituted 1,4-benzothiepine-1,1-dioxide derivatives, pharmaceutical compositions containing them and their use |
DE102007002260A1 (en) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome |
DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
DE102007008420A1 (en) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | benzimidazole derivatives |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
US8389514B2 (en) * | 2007-09-11 | 2013-03-05 | Kyorin Pharmaceutical Co., Ltd. | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors |
CN102344457B (en) | 2007-09-12 | 2015-07-22 | 杏林制药株式会社 | Spirocyclic aminoquinolones as GSK-3 inhibitors |
DE102007048716A1 (en) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo [1,2-a] pyrimidine derivatives |
DE102007063671A1 (en) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use |
WO2009097995A1 (en) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof |
DE102008017590A1 (en) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
AU2010221990B2 (en) * | 2009-03-11 | 2015-06-04 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as GSK-3 inhibitors |
BR112012003973A2 (en) | 2009-08-26 | 2015-09-08 | Sanofi Sa | crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011039338A2 (en) | 2009-10-02 | 2011-04-07 | Sanofi-Aventis | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
ES2687027T3 (en) | 2010-11-08 | 2018-10-23 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
WO2012120050A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120051A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
MX363161B (en) * | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease. |
ES2633766T3 (en) * | 2011-10-28 | 2017-09-25 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver diseases |
JO3301B1 (en) | 2013-04-26 | 2018-09-16 | Albireo Ab | Crystal modifications of elobixibat |
CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
JP6233979B2 (en) * | 2015-07-03 | 2017-11-22 | 本田技研工業株式会社 | Light source unit and vehicle room light |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
JP7391048B2 (en) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100687A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
DK4069360T3 (en) | 2019-12-04 | 2024-02-26 | Albireo Ab | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4188541A1 (en) | 2020-08-03 | 2023-06-07 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023549226A (en) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | Odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3389144A (en) * | 1965-06-08 | 1968-06-18 | Mcneilab Inc | 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols |
US3287370A (en) * | 1965-06-08 | 1966-11-22 | Mcneilab Inc | Tetrahydrobenzothiepins |
DE1593760A1 (en) | 1967-02-01 | 1972-06-08 | Boehringer Sohn Ingelheim | Process for the production of new benz-epine derivatives |
US3444176A (en) * | 1967-04-28 | 1969-05-13 | Mcneilab Inc | Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof |
GB1269551A (en) | 1969-03-27 | 1972-04-06 | Science Union & Cie | New tricyclic derivatives and process for their manufacture |
US3694446A (en) * | 1970-02-24 | 1972-09-26 | William J Houlihan | 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines |
CH537404A (en) | 1970-09-24 | 1973-05-31 | Sandoz Ag | Benzocyclo heptathiophene prodn - esp 4-(amino alkylidene) -4h- benzo (4,5) cyclohepta(1,2-b) thiophene-10 (9h) - ones from the |
CH531000A (en) * | 1970-03-11 | 1972-11-30 | Sandoz Ag | Process for the preparation of new benzocycloheptathiophenes |
US3821249A (en) * | 1970-03-13 | 1974-06-28 | En Nom Collectif Science Union | Dibenzothiazefin derivatives |
US3758528A (en) * | 1970-03-13 | 1973-09-11 | Science Union & Cie | Tricyclic compounds |
GB1428110A (en) | 1972-05-30 | 1976-03-17 | Reckitt & Colmann Prod Ltd | Pharmaceutical antihypertensive and vasodilator compositions |
CH582699A5 (en) * | 1973-03-26 | 1976-12-15 | Sandoz Ag | |
US3954764A (en) * | 1973-03-30 | 1976-05-04 | Hoffmann-La Roche Inc. | Dibenzo [b,f]thiepins bearing piperazinyl substitution |
US4044010A (en) * | 1973-03-30 | 1977-08-23 | Hoffmann-La Roche Inc. | Dibenzo[b,f] thiepins bearing piperazinyl substitution |
CH593970A5 (en) | 1973-03-30 | 1977-12-30 | Hoffmann La Roche | 10-(4-Substd. piperazino) dibenzo (b,f) thiepins - CNS depressants without cataleptic side-effects |
US3928383A (en) * | 1973-06-08 | 1975-12-23 | Hoffmann La Roche | Propynylamine-substituted dibenzo{8 b,f{9 thiepins and dibenz{8 b,f{9 oxepins |
SE7504508L (en) * | 1974-05-10 | 1975-11-11 | Ciba Geigy Ag | NEW HETEROCYCLIC S-IMINO-S-OXIDES. |
SE420725B (en) * | 1974-09-26 | 1981-10-26 | Ciba Geigy Ag | SET TO PREPARE 2,3-DIHYDRO-1-BENSTIEPIN-4-CARBOXYLIC ACID AMID |
US4247553A (en) * | 1977-10-31 | 1981-01-27 | The Upjohn Company | Methods of treating psychosis |
US4153612A (en) * | 1977-10-31 | 1979-05-08 | The Upjohn Company | 2-Benzoxepins |
US4251526A (en) * | 1977-10-31 | 1981-02-17 | Mccall John M | 2-Benzothiepins and compositions and methods of use therefore |
US4207239A (en) * | 1977-10-31 | 1980-06-10 | The Upjohn Company | Benzothiepins |
US5169857A (en) * | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
AU548253B2 (en) | 1981-05-11 | 1985-12-05 | Pierre Fabre S.A. | Benzoxepine derivatives and sulphur and nitrogen analogues thereof |
AU597671B2 (en) | 1986-06-20 | 1990-06-07 | Suntory Limited | 2-Phenylbenzoxepin derivative |
AU626881B2 (en) * | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
US5164387A (en) * | 1988-07-14 | 1992-11-17 | Hoffmann-Laroche Inc. | Condensed heterocyclic compounds |
US5158943A (en) * | 1988-11-21 | 1992-10-27 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
FR2661676A1 (en) | 1990-05-02 | 1991-11-08 | Lipha | Aminobenzocycloalkane derivatives, preparation processes and medicaments containing them |
JPH0825973B2 (en) | 1991-04-12 | 1996-03-13 | シェリング・コーポレーション | Bicyclic amides as inhibitors of acyl coenzyme A: cholesterol acyltransferase |
EP0549967B1 (en) * | 1991-12-20 | 1996-03-13 | Hoechst Aktiengesellschaft | Polymers and oligomers of bile-acids, process for their production and their use as medicines |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
FR2698873B1 (en) | 1992-12-07 | 1995-02-24 | Lipha | Benzocycloheptenes, benzoxepines and benzothiepins activators of potassium channels, preparation process, pharmaceutical composition containing them. |
US5594001A (en) * | 1993-04-08 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders |
US5491152A (en) * | 1994-03-23 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis |
US6107494A (en) * | 1994-09-13 | 2000-08-22 | G.D. Searle And Company | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6262277B1 (en) * | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
DK0781278T3 (en) | 1994-09-13 | 2001-04-17 | Monsanto Co | New benzothiepines which have activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
US6034118A (en) * | 1994-11-04 | 2000-03-07 | Gilead Sciences, Inc. | Thiepane compounds |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
US5721103A (en) * | 1994-12-30 | 1998-02-24 | Ligand Pharmaceuticals Incorporated | Trienoic retinoid compounds and methods |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5886016A (en) * | 1995-09-15 | 1999-03-23 | G.D. Searle & Co. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
JPH11515025A (en) * | 1995-11-02 | 1999-12-21 | ワーナー−ランバート・コンパニー | Methods and pharmaceutical compositions for regulating lipid concentration |
GB9601697D0 (en) | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
EP0888333B1 (en) | 1996-03-11 | 2005-08-31 | G.D. Searle LLC | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6251852B1 (en) * | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
SK125099A3 (en) | 1997-03-11 | 2001-02-12 | Searle & Co | Combination of ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors |
IT1292092B1 (en) | 1997-06-05 | 1999-01-25 | Geange Ltd | USE OF NITROGEN AROMATIC HETEROCYCLIC DERIVATIVES IN THE TOPICAL TREATMENT OF EPITHELIAL TISSUES |
GB9714274D0 (en) * | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
DE19755480A1 (en) | 1997-12-13 | 1999-06-24 | Gruenenthal Gmbh | Substituted heterocyclic benzocycloalkenes and their use as analgesic substances |
RU2236406C2 (en) * | 1997-12-19 | 2004-09-20 | Г.Д. Серл Энд Ко. | Method for preparing enantiomerically enriched tetrahydrobenzothiepine oxides |
DE19825804C2 (en) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US6355672B1 (en) * | 1998-08-07 | 2002-03-12 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
CA2337307A1 (en) * | 1998-08-20 | 2000-03-02 | Osamu Nishimura | Quaternary ammonium salts and their use |
AU1690100A (en) * | 1998-12-21 | 2000-07-12 | Takeda Chemical Industries Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
WO2000038725A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
DE19916108C1 (en) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use |
WO2001068637A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
US20020061888A1 (en) * | 2000-03-10 | 2002-05-23 | Keller Bradley T. | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
-
1999
- 1999-09-20 US US09/398,315 patent/US6221897B1/en not_active Expired - Lifetime
-
2001
- 2001-02-02 US US09/773,772 patent/US6441022B1/en not_active Expired - Lifetime
-
2002
- 2002-07-24 US US10/201,050 patent/US6642269B2/en not_active Expired - Lifetime
-
2003
- 2003-06-27 US US10/606,771 patent/US7019023B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040087648A1 (en) | 2004-05-06 |
US6642269B2 (en) | 2003-11-04 |
US6221897B1 (en) | 2001-04-24 |
US6441022B1 (en) | 2002-08-27 |
US7019023B2 (en) | 2006-03-28 |
US20030017996A1 (en) | 2003-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6221897B1 (en) | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use | |
AU752633B2 (en) | Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use | |
US6277831B1 (en) | 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use | |
US20100063124A1 (en) | New pyrazole derivatives and diabetic medicine containing them | |
SK182999A3 (en) | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders | |
US6602899B1 (en) | β-D-5 thioxylose derivatives, preparation method and therapeutic use | |
MXPA00012207A (en) | Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use | |
JPH1160484A (en) | Tnf production inhibitor | |
MXPA01009941A (en) | 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789 Effective date: 20050901 Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789 Effective date: 20050901 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |